Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Public ClinicalTrials.gov record NCT00006055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II. Determine the kinetics of T- and B-cell immune reconstitution after a combination of timed plasmapheresis, high dose cyclophosphamide and total lymphoid irradiation, and posttransplant immunosuppression with cyclosporine in these patients. III. Determine whether this treatment regimen beneficially influences the clinical course of these patients.
Study identification
- NCT ID
- NCT00006055
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 10 participants
Conditions and interventions
Conditions
- Purpura, Schoenlein-Henoch
- Graft Versus Host Disease
- Anemia, Hemolytic, Autoimmune
- Rheumatoid Arthritis
- Churg-Strauss Syndrome
- Hypersensitivity Vasculitis
- Wegener's Granulomatosis
- Systemic Lupus Erythematosus
- Giant Cell Arteritis
- Pure Red Cell Aplasia
- Juvenile Rheumatoid Arthritis
- Polyarteritis Nodosa
- Autoimmune Thrombocytopenic Purpura
- Takayasu Arteritis
Interventions
- anti-thymocyte globulin Drug
- cyclophosphamide Drug
- cyclosporine Drug
- filgrastim Drug
- methylprednisolone Drug
- prednisone Drug
- Autologous Peripheral Blood Stem Cell Transplantation Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 1 Year to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2000
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 23, 2005
Started 2000
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fairview University Medical Center | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2005 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00006055 live on ClinicalTrials.gov.